Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press54110.36691/RJA541ArticlesСтатьиResearch ArticleFEATURES OF BACTERIAL IMMUNOMODULATORS INFLUENCE ON IMMUNOREGULATORY MECHANISMS IN PATIENTS WITH RESPIRATORY ALLERGIESОсобенности влияния бактериальных иммуномодуляторов на иммунорегуляторные механизмы у больных с респираторной аллергиейSobolevA VСоболевАлексей Владимирович

Kashkin Research Institute of Medical Mycology

НИИ медицинской микологии имени П.Н. Кашкина

isobolev757@rambler.ruAakO VАакО В

Kashkin Research Institute of Medical Mycology

НИИ медицинской микологии имени П.Н. Кашкина

North-Western State Medical University named after I.I. MechnikovСеверо-Западный государственный медицинский университет им. И.И. Мечникова15122014116NO6 (2014)№6 (2014)707510032020Copyright ©; 2014, Pharmarus Print MediaCopyright ©; 2014, Фармарус Принт Медиа2014Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/541

Recovering from bacterial infections in the first years of life reduces further risk of allergic diseases. Effects of bacterial immunomodulator Broncho Vaxom on immune system to certain extent repeats the immune response that occurs during penetration of the pathogen in the body. Bacterial antigens orchestrate cellular and humoral immune responses, stimulate innate immunity, normalize cytokine balance, and are promising in the treatment of respiratory allergic diseases.

Бактериальные инфекции, перенесенные в первые годы жизни, уменьшают в дальнейшем риск развития аллергических заболеваний. Воздействие бактериального иммуномодулятора Бронхо-Ваксома на иммунную систему в значительной степени стимулирует иммунный ответ, аналогичный возникающему при проникновении патогена в организм. Бактериальные антигены активизируют клеточный, гуморальный ответ и врожденный иммунитет, нормализуют цитокиновый баланс и перспективны для использования с целью профилактики и в лечении респираторных аллергических заболеваний.

allergyimmunotherapybacterial lysates (Broncho-Vaxom)аллергические заболеванияиммунотерапиябактериальные лизаты (Бронхо-Ваксом)Bousquet J., Khaltaev N., Cruz A.A. et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008, v. 63, p. 8-160.Papadopoulos N.G., Agache I., Bavbek S. et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin. Translational Allergy. 2012, v. 2, 23 p.Sharpe R.A., Bearman N., Thornton C.R. et al. Indoor fungal diversity and asthma: A meta-analysis and systematic review of risk factors. J. Allergy Clin.Immunol. 2014, doi: 10.1016/j. jaci.2014.07.002.Соболев А.В., Аак О.В. Клиника, диагностика и лечение микогенной аллергии. Проблемы медицинской микологии. 2012, № 1, с. 37-40.Аак О.В., Фролова Е.В., Учеваткина А.Е. и соавт. Микогенная сенсибилизация и степень тяжести атопического дерматита. Проблемы медицинской микологии. 2013, № 3, с. 10-13.Strachan D.P. Hay fever, hygiene, and household size. B.M.J. 1989, v. 18, p. 1259-1260.Strachan D.P. Family size, infection and atopy: the first decade of the «hygiene hypothesis». Thorax. 2000, v. 55, р. 2-10.Mallia P., Johnston S.L. Respiratory viruses: do they protect from or induce asthma? Allergy. 2002, v. 57, p. 1118-1129.Asher M.I., Stephen Montefort, Bengt Bjorkst et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006, v. 368, p. 733-743.Renz H., Herz U. The bidirectional capacity of bacterial antigens to modulate allergy and asthma. Eur.Respir. J. 2002, v. 19, p. 158-171.Bona C. Neonatal immunity. Totowa, NJ, Humana Press. 2005, 389 p.Hopfenspirger M.T., Agrawal D.K. Airway Hyperresponsiveness, Late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice. J. Immunol. 2002, v. 168, p. 2516-2522.Arnoldussen D.L., Linehan M., Sheikh A., BCG vaccination and allergy: A systematic review and meta-analysis. J. Allergy Clin. Immunol. 2011, v. 127, p. 246-253.Guilbert T.W., Denlinger L.C. Role of infection in the development and exacerbation of asthma. Expert Rev. Resp. Med. 2010, v. 4, p. 71-83.Воробьева О.В., Гущин И.С. Исторические предпосылки создания метода аллергенспецифической иммунотерапии (К 100-летию открытия). Рос. Аллергол. Журн. 2010, № 5, с. 17-28.Frankland A.W., Hughes W.H., Gorrill R.H. Autogenous bacterial vaccines in treatment of asthma. B.M.J. 1955, v. 2, p.941-944.Vaccine therapy in asthma (Leading article). B.M.J. 1966, v. 1, p. 186-187.Berche P., Veron M., Tinelli R. An acellular vaccine from «Pseudomonas aeruginosa». I. Preparation and activity (author’s transl). Ann. Microbiol. (Paris). 1976, v. 127, p. 247-259.Golebiowski T.E., Tinelli R.L. Protective action on mice of acellular extracts from Salmonella typhimurium. C.R. Acad. Sci. Hebd. Seances Acad. Sci. D. 1978, v. 286, p. 1633-1635.Villa E., Garelli V., Braido F. et al. May we strengthen the human natural defenses with bacterial lysates? World Allergy Organ. J. 2010, v. 3, р. 17-23.Bauer J.A., Salvagni M., Vigroox J.P.L. et al. Bacterial extract for respiratory disorders and process for its preparation. Patent USA 8697154, 2014.Alyanakian M.A., Grela F., Aumeunier A. et al. Bach J-F. Transforming growth factor-β and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes. 2006, v. 55, p.179-185.Fontanges R., Bottex C., Cristau B., Burckhart M.F. Influence of a bacterial extract on antigen presentation and protection against experimental infections. Lung. 1990, v. 168, p. 716-719.Bessler W.G. The bacterial extract Broncho-Vaxom protects against respiratory infections - in vivo and in vitro studies. In «Microbial pathogens and strategies for combating them: science, technology and education» Badajoz (Spain): Formatex Research Center. 2013, v. 3, p. 1934-1940.Puigdollers J.M., Serna G.R., Hernandez del Rey I. et al. Immunoglobulin production in man stimulated by an orally administered bacterial lysate. Respiration. 1980, v. 40, p. 142-149.Schaad U.B. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J. Pediatr. 2010, v. 6, p. 5-12.Weinberger M. Can we prevent exacerbations ofasthma caused by common cold viruses? J. Allergy Clin. Immunol. 2010, v. 126, p. 770-771.Podleski W.K. Immunomodulation of allergic autocytotoxicity in bronchial asthma by a bacterial lysate - Broncho-Vaxom. Int. J. Immunopharmacol. 1985, v. 7, p. 713-718.Rozy A., Chorostowska-Wynimko J. Bacterial immunostimulants - mechanism of action and clinical application in respiratory diseases. Pneumonol. Alergol. Pol. 2008, v. 76, p. 353-359.Luan H., Zhang Q., Wang L. et al. OM85-BV induced the productions of IL-1ß, IL-6, and TNFa via TLR4- and TLR2-mediated ERK1/2/NF-kB pathway in RAW264.7 cells. J. Interferon Cytokine Res. 2014, v. 34, p. 526-536.Navarro S., Cossalter G., Chiavaroli C. et al. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T-cells to the airways. Mucosal Immunology. 2011, v. 4, p. 53-65.Byl B., Libin M., Gérard M. et al. Bacterial extract OM85-BV induces interleukin-12-dependent IFN-gamma production by human CD4+ T-cells. J. Interferon Cytokine Res. 1998, v. 18, p. 817-821.A bacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. Am. J. Rhinol. Allergy. 2014, v. 28, p. 110-116.Gambillara E., Wassenberg J., Audran R. et al. Effect of oral BroncoVaxom on nasal challenge with grass pollen in patients with allergic rhinitis. SSAI Conf., Geneva, 2009.